Association of Performance on the Financial Capacity Instrument–Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published February 8, 2022.
Article Versions
- Previous version (February 8, 2022 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Maria Vassilaki, MD, PhD, MPH,
- Jeremiah A. Aakre, MPH,
- Walter K. Kremers, PhD,
- Michelle M. Mielke, PhD,
- Yonas E. Geda, MD, MSc,
- Mary M. Machulda, PhD,
- David S. Knopman, MD,
- Prashanthi Vemuri, PhD,
- Val J. Lowe, MD,
- Clifford R. Jack Jr., MD,
- Erik D. Roberson, MD, PhD,
- Adam Gerstenecker, PhD,
- Roy C. Martin, PhD,
- Richard E. Kennedy, MD, PhD,
- Daniel C. Marson, PhD, JD and
- Ronald C. Petersen, MD, PhD
- Maria Vassilaki, MD, PhD, MPH,
NONE
NONE
NONE
(1) Journal of Alzheimer's Disease, Associate Editor (2019-present); (2) Frontiers in Neuroscience (Neurodegeneration) Guest Editor for Research Topic collection
NONE
NONE
NONE
(1) F. Hoffmann-La Roche Ltd, consultant (payment to my institution), 2021
NONE
NONE
NONE
(1) F. Hoffmann-La Roche Ltd; (2) Biogen
1) NIA, AG057708, co-Investigator and site PD/PI, 2018- present (2) NIA U01 AG06786, co-Investigator, 2019-present (3) NIA, RF1 AG057181, co-Investigator, 2018-present (4) NIA, R01 AG060920, co-Investigator, 2019 -present (5) NIA, R01 AG068192, co-Investigator, 2020 -present (6) NIA, R01 AG068007, co-Investigator, 2020 -present
(1) St. AnneÂs University Hospital Brno, International Clinical Research Center, Czech Republic/EU Stock/Stock Options, Medical Equipment & Materials: Spouse (K. Papadakis) and I have stocks in (1) Abbott Laboratories (2020-present); (2) Johnson and Johnson (2018- present); (3) Medtronic (2020-present); and (4) Amgen (2019- present).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeremiah A. Aakre, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Walter K. Kremers, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) AstraZeneca. This is unrelated to this project and there is no conflict of interest. 2) Biogen - Predicting Elevated Brain Amyloid-Beta among Individuals with Cognitive Impairment 3) Roche - Epidemiology of Alzheimer's Disease
NIA U01AG 06786 (Petersen) Co-I 07/15/2019 - 06/30/2024 Alzheimers Disease Patient Registry NIA P30AG 62677 (Petersen) Core Leader 07/01/2019 - 04/30/2024 Mayo Alzheimer's Disease Research Center NIDDKD RO1DK 90358 (Rule) Co-I 03/15/2016 Â 01/31/2022 The Aging Kidney Anatomy Study NIH R01AG 59009 (Petersen) Co-I 09/01/2018 Â 06/30/2023 Validation of Online Methods to Predict and Monitor Cognitive Decline NIND R01NS 97495 (Vemuri) Co-I 09/01/2016 Â 05/31/2021 Development, Validation, and Application of an Imaging Based CVD Scale NINDS U01NS 100620 (Kantarci) Co-I 09/25/2017 Â 08/31/2022 Longitudinal Imaging Biomarkers of Disease Progression in DLB Juvenile Diabetes Research Foundation 2-SRA-2017-503-M-B (Kudva) Co-I 08/01/2017 Â 07/31/2019 Harnessing Non-Glucose Feedback Signals for Automatic Glucose Control in Type 1 Diabetes: Confronting Exercise- Safety and Stress-Aware Control NIAMSD R01AR 73147 (Maradit Kremers) Co-I 03/01/2018 Â 02/28/2023 Enhance Arthroplasty Research through Electronic Health Records and NLP- enabled Informatics NIDDKD R01DK 120358 (Kudva) Co-I 09/30/2018 Â 07/31/2021 Automated Glucose Regulation To Improve Diabetes Control and Outcomes for Pregnant Women with Type 1 Diabetes and Fetus U19AG 63911 (Boeve) Core Leader 09/15/2019 - 06/30/2024 ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) NIDDK R01DK 125252 (Kumar) Co-I 07/09/2020 Â 05/31/2023 Fractures and bone disease in living kidney donors R56AG 68206 (Schwarz) 09/15/2020 -08/31/2022 Protecting the Confidentiality of Participants in Studies of Alzheimer's Disease and Related Dementias by Replacing Face Imagery in MRI NIA R01AG 57708 (Vassilaki) Co-I 05/01/2018 Â 02/28/2022 Pathways Linking Neuropsychiatric Symptoms with AlzheimerÂs Disease Neuroimaging Biomarkers and the Outcome of Incident Mild Cognitive Impairment/Dementia NIA RF1AG 55151 (Mielke) Co-I 05/01/2017 Â 04/30/2022 Reproductive Risk Factors for AlzheimerÂs Disease Dementia and Pathology NIAMSD R01AG 60950 (Maradit Kremers) Co-I 03/01/2019-11/30/2023 Risk of Cognitive Impairment and Dementia in Total Joint Arthroplasty NIH/NIAMSD R01AR 71338 (Zhao) Co-I 05/01/2017 Â 04/30/2022 4DCT Imaging for Improved Diagnosis and Treatment of Wrist Ligament Injuries
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michelle M. Mielke, PhD,
- Yonas E. Geda, MD, MSc,
Data Safety Monitoring Board.
NONE
International Clinical Research Center (in part funded by European Union) travel funding for annual advisory board meeting in Brno, Czech republic
2013 to present : Member, editorial board of International Psychogeriatrics. 2015 to present. Member, Editorial board of the Journal of Neuropsychiatry and Clinical Neuroscience
NONE
NONE
NONE
Served as a one time advisory board member for Lundbeck in March of 2017.
NONE
NONE
NONE
10% research effort (Co-I) funded by ROCHE (ended on December 31 of 2018) Site PI of Green Valley project at Barrow Neurological Institute
National Institute on Aging/NIH R01AG057708 (Principal investigator).
Research Professor, Arizona State University
1-Harold Amos Medical Faculty Development Award (RWJ foundation). 2- European Union Regional Development Fund (CZ.1.05/1.1.00/02.0123)
NONE
NONE
NONE
NONE
NONE
NONE
- Mary M. Machulda, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Co-Investigator National Institutes of Health; R01 AG 50603-1; 4/2016 Â 3/20201 (2) Co-Investigator National Institutes of Health; R01 DC 12519-4; 7/2013 - 06/2018 (3) Co-Investigator Core B - Clinical - Rochester in: Mayo Alzheimer's Disease Research Center. Funded by National Institute on Aging. (P50 AG 16574) 05/01/2014 - 04/30/2019 (4) Co-Investigator - Alzheimer's Disease Patient Registry/Mayo Clinic Study of Aging. Funded by National Institute on Aging. (U01 AG 06786) 07/01/2014 - 06/30- 2019 Mayo Alzheimer's Disease Research Center. Funded by National Institute on Aging. (P50 AG 16574) 05/01/2014 - 04/30/2019 (5) Primary Investigator National Institutes of Health; R01 AG49810-1; 04/01/2016 - 02/28/2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Knopman, MD,
DIAN study DSMB (Sept 2013 - July 2019; August 2020 - present). Dr. Knopman serves on a Data Safety monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation. He served as a consultant for Samus Therapeutics, Third Rock, Roche, Magellan Health and Alzeca Biosciences but receives no personal compensation. In all of these activities, consulting fees are paid to Dr. Knopman's institution, Mayo Clinic, and he has no control or use of the consulting fees.
NONE
NONE
Scientific Integrity officer of Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) A4 clinical trial partially funded by Lilly (site PI) (2) Biogen Alzheimer Study (site PI)
NIH: R01-AG11378 ongoing, R01 AG41851; P30-AG 62677 (Mayo AlzheimerÂs Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Prashanthi Vemuri, PhD,
NONE
NONE
Miller Medical Communications Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
PV is funded by NIH grants (R01 NS097495 and R01 AG056366).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Val J. Lowe, MD,
(1) Piramal Imaging (2) Merck Research, INC (3) Bayer Schering Pharma (4) AVID Radiopharmaceuticals (5) Eisai Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) GE Health Care (2) AVID Radiopharmaceuticals (3) Siemens Molecular Imaging
(1) NIA R01 DC010367-01, CoI, 12/01/09-11/30/14 (2) NIA P50 AG016574-12, Co-PI Project #1, 05/01/09- 04/30/14 (3) NIA R01 AG011378-16, CoI, 06/01/08-05/31/13 (4) NCI R01 R01CA 200551-1 , CoI, 02/01/16-11/30/19 (6) P50 CA102701-07, CoI, 09/01/08-08/31/13 (7) R01 CA125614-04 , CoI,09/26/06-07/31/11 (8) R21 CA123909-02, CoI, 07/01/07-08/01/12 (9) U01AG 06786-30, CoI, 07/01/07-06/30/19 (10) UM1CA 186686-2,CoI, 04/17/14-02/28/19 (11) R01 AG41851-4, CoI, 04/01/12-03/28/17 (12)P50 AG44170-4, CoI, 09/01/12-05/31/17 (13)R01 DC012519-1, CoI, 07/01/13-06/30/18 (14)R01CA 154348-4, CoI, 07/18/14-12/31/16 (15)R21AG 47984-1, PI, 09/01/15-05/31/17 (16)R01NS 89757-1, CoI, 09/15/15-08/31/20
NONE
(1) MN Partnership for Biotechnology and Medical Genomics (2) Elsie and Marvin Dekelboum Family Foundation (3) Liston Family Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Clifford R. Jack Jr., MD,
iDMC for Roche no payment involved
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Eisai - no payments made
NONE
Biogen - consultant with no financial compensation Roche - iDSMB with no financial compensation Eisai - speaker with no financial compensation
NONE
NONE
National Institutes of Health: R37-AG011378, RO1- AG041851, U01-AG06786, U01-AG024904, R01-AG37551, R01- AG043392, R01-NS092625, R01 AG50745, UF1 AG32438, R01 AG49704, R01 AG50745, R01 AG40282, R01 AG54491, R01 AG41705, R01 AG51406, R01AG054029, R01 AG55151, R01 AG56366, R01 AG55444, R01 AG46179
NONE
The Alexander Family Professorship for Alzheimer's disease Research, Mayo Clinic and the GHR Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Erik D. Roberson, MD, PhD,
(1) Biogen (2) AVROBIO (3) AGTC (4) Lilly
NONE
NONE
(1) Brain Research, Senior Editor, 2017-19 (2) J. Neuroscience, Associate Editor, 2014-19 (3) Frontiers in Neuroscience, Associate Editor, 2010- (4) Frontiers in Neurology, Associate Editor, 2018-
(1) Methods and Compositions for Reducing Amyloid beta Levels (2) Agents That Reduce Neuronal Overexcitation, related to tau
Amthor, F.R., A.M. Theibert, D.G. Standaert, and E.D. Roberson. (2020). Essentials of Modern Neuroscience. (New York: McGraw-Hill Companies, Inc.).
NONE
NONE
NONE
Weston Brain Institute, grant reviews NIH, grant reviews
NONE
Alector, Biogen
NIH
NONE
BrightFocus Foundation, Alzheimer's Drug Discovery Foundation, Bluefield Project, Alzheimer's Association
NONE
(1) Conditional tau knockout mice, Genentech
NONE
NONE
NONE
NONE
- Adam Gerstenecker, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) HAMMS: Hippocampal internal Architecture and iflaMmatory biomarkers in Multiple Sclerosis, K23HD091849, PI, 09/12/2018 Â 08/31/2023. (2) Validation of Online Measures to Predict and Monitor Cognitive Decline, R01AG059009, Co-I, 09/01/18 Â 08/31/23. (3) Innate and Adaptive Immunity in Parkinson Disease - Core B: Clinical Research Core, P50NS108675, Co-I, 08/01/18 Â 06/30/23.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roy C. Martin, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/1R01 AG059009, Investigator 2018-2023 NICHD/1R01 HD102723-01A1, Investigator 2021-2026 NINDS-NeuroPace,Inc/1UH3NS109557-01A1, Investigator 2021-2026 NINDS/UH3NS100553, Investigator 2016-2023
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Richard E. Kennedy, MD, PhD,
NONE
NONE
NONE
Associate Editor, Alzheimer's & Dementia: Translational Research and Clinical Interventions, 2015-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH/NIA, R01 AG060993, PI, 02/15/2019-present (2) NIH/NINDS, R01 NS102257, Biostatistician, 04/01/2018 Â present (3) NIH/NINDS, P50NS108675, Biostatistician, 9/30/2018 Â present (4) NIH/DHHS, R01AG059009, Biostatistician, 09/01/2018 Â present (5) Administration for Community Living, 90DPTB0015, Biostatistician, 09/30/2017-present (6) VA Rehabilitation R&D, VA RRD E1995-R, Biostatistician, 04/01/2016- present (7) NIH/NIA, R01 AG057684, PI, 09/15/2017-present (8) NIH/NINDS, R01 NS107316, Biostatistician, 06/01/2018 Â present (9) NIH/NINR, R01 NR017181, Biostatistician, 09/21/2018 Â present (10) VA HSR&D, IIR 19-413-2, Biostatistician, 07/01/2020 Â present (11) NIH/NIA, RF1 AG072773, Biostatistician, 05/01/2021 Â present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel C. Marson, PhD, JD and
NONE
NONE
NONE
NONE
NONE
Dr. Marson received an initial honoraria upon signing agreement for writing book entitled: (1) Clinical and Forensic Assessment of Financial Capacity; Publisher: Oxford University Press; Expected publication date 2022
NONE
NIH/NIA grant - consultant
NONE
NONE
NONE
NONE
(1) NIH ADNI-3 grant, AG24904, consultant, (2020-2021) (2) NIH grant AG0059009; consultant through company Financial Cognition Assessments LLC, (2020-2021)
NONE
NONE
NONE
NONE
(1) Inventor of Financial Capacity Instrument and Financial Capacity Instrument--Short Form which are both owned by UAB Research Foundation (2) Contributed to development of e-FCI electronic instrument.
NONE
NONE
Hood law firm, expert witness, 2020-2021 Twenge-Twombley law firm, expert witness, 2018-2021 Friedman law firm, expert witness, 2020-2021 Lee law firm, expert witness, 2020-2021 Efron law firm, expert witness, 2020-2021
- Ronald C. Petersen, MD, PhD
Genentech - DSMB
NONE
NONE
NONE
NONE
Mild Cognitive Impairment,Oxford University Press, 2003 UpToDate
NONE
(1) Roche, (2) Biogen, (3), Eisai, (4) Merck, (5) Nestle (As noted in question 1, DSMB for Genentech.)
NONE
NONE
NONE
NONE
National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-2018) U01-AG024904 (Site PI) (2004-present) U24-AG057437 (Co-PI) (2018-present) P30 AG062677 (PI) (2019 - present) U01NS 125417 (Site PI) (2021 Â present)
NONE
(1) GHR Foundation, (2) Mayo Medical Foundation for Education and Research
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Quantitative Health Sciences (MV, JAA, WKK, M.M. Mielke, RCP), and Department of Neurology (M.M. Mielke, DSK, RCP), Mayo Clinic, Rochester, MN; Department of Neurology (YEG), Barrow Neurological Institute, Phoenix, AZ; Department of Psychiatry and Psychology (M.M. Machulda), and Department of Radiology (PV, VJL, CRJ), Mayo Clinic, Rochester, MN; Department of Neurology (EDR, AG, RCM, DCM), Department of Medicine (REK), and Alzheimer's Disease Center (DCM), University of Alabama at Birmingham.
- Correspondence
Dr. Vassilaki vassilaki.maria{at}mayo.edu
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.